This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Bremelanotide administered subcutaneously at doses of 1.25 and 1.75 mg significantly increased the number of satisfying sexual events per month and improved scores on female sexual function and distress scales compared to placebo in premenopausal women with sexual dysfunction.
Why it matters
This study provides evidence that bremelanotide is a promising treatment option for female sexual dysfunction, a condition with limited pharmacological therapies. It supports further development of melanocortin receptor agonists for sexual health.
How the study worked
A randomized, placebo-controlled, dose-finding trial was conducted with 327 premenopausal women who self-administered bremelanotide or placebo subcutaneously as desired over 12 weeks. Primary and secondary endpoints measured changes in sexual satisfaction and function.
What this study cannot tell us
The study duration was relatively short at 12 weeks, and long-term safety and efficacy remain unknown. The evidence strength and study type were not clearly specified, limiting full assessment of the findings.
Read the original research
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Women's health (London, England), 12(3), 325-37
Citation
Clayton, Anita H; Althof, Stanley E; Kingsberg, Sheryl; DeRogatis, Leonard R; Kroll, Robin; Goldstein, Irwin; Kaminetsky, Jed; Spana, Carl; Lucas, Johna; Jordan, Robert; Portman, David J. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.. Women's health (London, England), 12(3), 325-37. https://doi.org/10.2217/whe-2016-0018